Immuron (IMC) Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
IMC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Immuron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.028 |
| 52 Week High | AU$0.098 |
| 52 Week Low | AU$0.027 |
| Beta | 0.43 |
| 1 Month Change | -17.65% |
| 3 Month Change | -54.84% |
| 1 Year Change | -64.10% |
| 3 Year Change | -65.00% |
| 5 Year Change | -86.00% |
| Change since IPO | -99.72% |
Recent News & Updates
Recent updates
We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate
Mar 08
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth
Jan 20We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth
Oct 01We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth
Mar 30Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?
Feb 05
Peter Anastasiou Is The Executive Vice Chairman of Immuron Limited (ASX:IMC) And They Just Sold 100% Of Their Shares
Jun 20Do Directors Own Immuron Limited (ASX:IMC) Shares?
Jun 16Shareholder Returns
| IMC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -3.4% | -2.1% | -2.7% |
| 1Y | -64.1% | -45.2% | 8.8% |
Return vs Industry: IMC underperformed the Australian Biotechs industry which returned -45.2% over the past year.
Return vs Market: IMC underperformed the Australian Market which returned 8.8% over the past year.
Price Volatility
| IMC volatility | |
|---|---|
| IMC Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.9% |
Stable Share Price: IMC's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: IMC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 7 | Steve Lydeamore | www.immuron.com.au |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
Immuron Limited Fundamentals Summary
| IMC fundamental statistics | |
|---|---|
| Market cap | AU$9.15m |
| Earnings (TTM) | -AU$4.65m |
| Revenue (TTM) | AU$7.48m |
Is IMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMC income statement (TTM) | |
|---|---|
| Revenue | AU$7.48m |
| Cost of Revenue | AU$2.72m |
| Gross Profit | AU$4.76m |
| Other Expenses | AU$9.41m |
| Earnings | -AU$4.65m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 63.69% |
| Net Profit Margin | -62.14% |
| Debt/Equity Ratio | 0% |
How did IMC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 23:26 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immuron Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Karen Sterling | Emerging Growth Research LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |